N/A N=20 Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
Stevens-Johnson Syndrome · Toxic Epidermal Necrolysis
Primary: Complete Skin Healing Time, Day, Medium [Full Range] — 10.0 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=135 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Phase 2 N=12 A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Sjögren-Larsson Syndrome
Primary: Number of Participants Experiencing a Serious Adverse Event (SAE). — 0; 0 Participants
Phase 3 N=11 RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
Sjogren-Larsson Syndrome
Primary: Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients — -0.7 units on a scale
Phase 2 N=150 Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Rash
Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769
Phase 2 N=3 Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Netherton Syndrome
Primary: Blood Pimecrolimus Levels — 0; 0; 0.312; 1.260 ng/mL
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=147 A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment — 71.2; 80.8 percentage of participants — p=0.175
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Early Phase 1 N=13 An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
Ichthyosis
Primary: Reduction in Total Ichthyosis Severity Score — -12.2 units on a scale
Phase 2 N=47 Tofacitinib for Immune Skin Conditions in Down Syndrome
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Phase 1 N=30 StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Skin Wound · Burns · Trauma-related Wound
Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants
Phase 1 N=117 A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject
Healthy
Primary: Skin Irritation Score of the Application Site — 0.237; 0.289; 0.250 Scores on a scale
N/A N=274 Pathogenesis of Adverse Drug Reactions
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Phase 3 N=153 The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
Ichthyosis
Primary: Change in Investigator Global Assessment (IGA) Score — 41.4; 44.9 percentage of responders — p=0.39
Phase 2 N=64 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo. — -6.2; -6.5; -6.2; -5.7 Scores on a scale — p=0.845
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Phase 1 N=12 Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
Primary Sjögren Syndrome
Primary: Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) Score From Baseline to Week 24 — -0.125 score on a scale
Phase 2 N=140 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome
Primary: Number of Participants (Percentage) With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment — 9; 11; 11; 12 Participants
Phase 3 N=169 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Phase 2 N=20 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Secondarily Infected Traumatic Lesions (SITL) · Impetigo
Primary: TD1414 Serum Concentration by Timepoint — 624.3; 864.1; 1195.7; 888.4 pg/mL
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 3 N=201 A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481
Phase 1 N=7 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Cutaneous Lupus
Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells
Phase 2 N=17 Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
Active Systemic · Onset Juvenile Idiopathic Arthritis
Primary: Number of Patients Completing Week 12 of Treatment — 9; 10; 0; 7 Participants
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
Phase 2 N=90 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.1; 59.5; 57.3 Percentage of…